BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alzial G, Renoult O, Paris F, Gratas C, Clavreul A, Pecqueur C. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene 2021. [PMID: 34764443 DOI: 10.1038/s41388-021-02056-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Urcun S, Baroli D, Rohan P, Skalli W, Lubrano V, Bordas SP, Sciumè G. Non-operable glioblastoma: proposition of patient-specific forecasting by image-informed poromechanical model.. [DOI: 10.1101/2023.01.10.523475] [Reference Citation Analysis]
2 Trifănescu OG, Trifănescu RA, Mitrică R, Mitrea D, Ciornei A, Georgescu M, Butnariu I, Galeș LN, Șerbănescu L, Anghel RM, Păun MA. Upstaging and Downstaging in Gliomas-Clinical Implications for the Fifth Edition of the World Health Organization Classification of Tumors of the Central Nervous System. Diagnostics (Basel) 2023;13. [PMID: 36673007 DOI: 10.3390/diagnostics13020197] [Reference Citation Analysis]
3 Hassan MH, Saleem TH, Ashraf O, Elsadek BE, Hamdan AR, El-sawy SA. Biochemical and neurosurgical analyses of circulating neuroglobin and somatic mutations in IDH1 gene in patients with traumatic brain injury. Egyptian Journal of Basic and Applied Sciences 2022;9:413-422. [DOI: 10.1080/2314808x.2022.2104073] [Reference Citation Analysis]
4 Babu D, Chintal R, Panigrahi M, Phanithi PB. Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma. Cell Oncol (Dordr) 2022. [PMID: 36284039 DOI: 10.1007/s13402-022-00729-x] [Reference Citation Analysis]
5 He Q, Chen J, Xie Z, Chen Z. Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance. Cancers (Basel) 2022;14. [PMID: 36497259 DOI: 10.3390/cancers14235779] [Reference Citation Analysis]
6 Zheng F, Pang Y, Li L, Pang Y, Zhang J, Wang X, Raes G. Applications of nanobodies in brain diseases. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.978513] [Reference Citation Analysis]
7 Ramachandraiah K, Thylur Puttalingaiah R. The role of mixed lineage kinase 3 (MLK3) in cancers. Pharmacology & Therapeutics 2022;238:108269. [DOI: 10.1016/j.pharmthera.2022.108269] [Reference Citation Analysis]
8 Majchrzak-celińska A, Sidhu A, Miechowicz I, Nowak W, Barciszewska A. ABCB1 Is Frequently Methylated in Higher-Grade Gliomas and May Serve as a Diagnostic Biomarker of More Aggressive Tumors. JCM 2022;11:5655. [DOI: 10.3390/jcm11195655] [Reference Citation Analysis]
9 Asija S, Chatterjee A, Yadav S, Chekuri G, Karulkar A, Jaiswal AK, Goda JS, Purwar R. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Int Rev Immunol 2022;:1-24. [PMID: 35938932 DOI: 10.1080/08830185.2022.2101647] [Reference Citation Analysis]
10 Renoult O, Gratas C, Joalland N, Laurent--blond M, Awada H, Bourgeois M, Oliver L, Chiavassa S, Croyal M, Paris F, Pecqueur C. Pyruvate carboxylation identifies Glioblastoma Stem-like Cells opening new metabolic strategy to prevent tumor recurrence.. [DOI: 10.1101/2022.07.18.500427] [Reference Citation Analysis]
11 D. Al-saadi T, J. Diaz R. Noncanonical (Non-R132H) IDH-Mutated Gliomas. Glioblastoma - Current Evidences [Working Title] 2022. [DOI: 10.5772/intechopen.105469] [Reference Citation Analysis]
12 Yusuf S, Aretz P, Nickel A, Westhoff P, Sharma A, Qin N, Remke M, Steiger H, Hänggi D, Liu H, Liu H, Neumann S, Reifenberger G, Maciaczyk J. WNT/β-Catenin-Mediated Resistance to Glucose Deprivation in Glioblastoma Stem-like Cells. Cancers 2022;14:3165. [DOI: 10.3390/cancers14133165] [Reference Citation Analysis]
13 Hills KE, Kostarelos K, Wykes RC. Converging Mechanisms of Epileptogenesis and Their Insight in Glioblastoma. Front Mol Neurosci 2022;15:903115. [DOI: 10.3389/fnmol.2022.903115] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]